ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

10 links0 made here, not in the record19 judgments2 judges (the rules as one: Rule based)3 record changes seen2 read an older version
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05536141A Phase 1 Study of AB521Monotherapy and CombinationTherapies in Renal CellCarcinoma and Other SolidTumorsArcus Biosciences, Inc.Phase 1 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Nov 13 · ClinicalTrials.gov record · Version of 2026-11-13Nov 13 · Rule based · Reading set asideNov 16 · Rule based · Read againRead againCONDITIONSCarcinoma, Renal CellThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionKidney NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedErythrocytosis, Familial, 4The registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termDRUGSCasdatifanIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCabozantinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 16 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerZimberelimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIpilimumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 16 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTivozanibIntervention entry›Nov 18 · Rule based · BackgroundBackgroundIvonescimabIntervention entry›Nov 18 · Rule based · BackgroundBackgroundAxitinibIntervention entry›Nov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Casdatifan

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Casdatifan”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 5The record itselfClinicalTrials.gov recordVersion of 2026-10-05Record change
Nov 2CasdatifanClaude Opus 5.5TestedRead an older version
Nov 2CabozantinibClaude Opus 5.5BackgroundReplaced
Nov 2ZimberelimabClaude Opus 5.5BackgroundRead an older version
Nov 2IpilimumabClaude Opus 5.5BackgroundReplaced
Nov 2The record itselfClinicalTrials.gov recordVersion of 2026-11-02Record change
Nov 13The record itselfClinicalTrials.gov recordVersion of 2026-11-13Record change
Nov 13The record itselfRule based · nightly checkReading set asideCurrent
Nov 14Carcinoma, Renal CellRule based · condition-kind ruleFinest filed termCurrent
Nov 14Kidney NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 14Erythrocytosis, Familial, 4Rule based · condition-kind ruleFinest filed termCurrent
Nov 16The record itselfRule based · nightly checkRead againCurrent
Nov 16CabozantinibClaude Opus 5.5Background · partnerCurrent
Nov 16IpilimumabClaude Opus 5.5Background · partnerCurrent
Nov 18CasdatifanRule based · role ruleTestedCurrent
Nov 18CabozantinibRule based · role ruleBackgroundAgrees
Nov 18ZimberelimabRule based · role ruleBackgroundCurrent
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
Nov 18TivozanibRule based · role ruleBackgroundCurrent
Nov 18IvonescimabRule based · role ruleBackgroundCurrent
Nov 18AxitinibRule based · role ruleBackgroundCurrent
As of nowCarcinoma, Renal CellRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.